Resumen

FELDMAN¹, Gabriela et al. Sulfhydryl groups giver and rosuvastatin action on bone in an experimental model of rats lead exposed. Insuf. card. [online]. 2016, vol.11, n.1, pp.40-46. ISSN 1852-3862.

Background. Lead is a metal that accumulates in bone; the tank and removal are still active physiology of calcium which is subject to general factors, such as nutrition, exercise, and specific factors such as hormonal and metabolic influences. Lead causes alterations in lipid and carbohydrate profile. For intoxication treatment, are used drugs such as sulfhydryl groups givers: N-adenosylmethionine and rosuvastatin used for dyslipidemias. Objective. In an animal model of rats exposed to 1000 ppm of lead acetate determine changes in bone structure and the effect of a sulfhydryl giver associated with rosuvastatin. Materials and methods. We worked with adult white Wistar rats, were formed five groups with N=6 each: group 1, intoxicated with 1000 ppm of lead (AcPb) acetate during a period of 1 month; group 2, intoxicated with 1000 ppm AcPb + treatment with rosuvastatin (0.16 mg/kg/day/rat, oral); group 3, intoxicated with 1000 ppm AcPb + treatment with N-adenosylmethionine (14 mg/kg/day/rat, intramuscular); group 4, intoxicated with 1000 ppm AcPb + treatment with rosuvastatin (0.16 mg/kg/day/rata) + N-adenosylmethionine (14 mg/kg/day/rat), and group 5, control group, with lead-free water. Lead in blood was determined by spectrophotometry of electrothermal atomization-atomic absorption and ALA-d erythrocyte (acid delta amino levulinic dehydratase) was measured as a biological marker of lead exposure. High resolution digital radiology was used to assess bone alterations in long bones of each animal, with a caliper of 1 cm. Equipment Radiology Kodak Direct View Elite CR. Results. Biological markers of exposure to the five groups showed the following results: group 1, ALA-D erythrocyte 6.4 ± 0.9 U/L and blood lead: 16.5 ± 3.8 mg/dL; Group 2, ALA-D erythrocyte 5.9 ± 0.9 U/L and blood lead: 15 ± 2.8 mg/dL; Group 3, ALA-D erythrocyte: 7.6 ± 0.8 U/L and blood lead: 13 ± 2.5 mg/dL; Group 4, ALA-D erythrocyte: 8.2 ± 0.8 U/L and blood lead: 11 ± 0.8 mg/dL, and group 5 (control with lead-free water): ALA-D erythrocyte: 17± 3.5 U/L and blood lead ≤ 5 mg/dL. In long bones (1000 ppm), radiopaque images were observed by mobilization of calcium and phosphorus in the diaphysis of them from lead, with modification of the bone marrow architecture. Conclusions. The findings of this work allow affirming that the use of givers of sulfhydryl groups more rosuvastatin would prevent the mobilization of calcium caused by lead; these associated drugs enhance their original therapeutic effects. Digital radiology is a sensitive method for evaluation structural changes caused by lead in bone.

Palabras clave : Lead; Experimental model; Bone; Rosuvastatin; N-adenosylmethionine.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )